blog about New Zika Virus Test Kit Enables Faster Diagnosis

Early and accurate diagnosis of Zika virus infection is crucial for effectively controlling outbreaks, guiding clinical treatment, and informing public health strategies. In this context, the Rapid Response™ Zika Virus IgG/IgM Antibody Rapid Test Kit, developed by BTNX, has emerged as a vital tool for supporting Zika virus diagnosis due to its convenience and speed.

Zika virus is primarily transmitted by Aedes mosquitoes and typically causes mild, nonspecific symptoms such as fever, rash, joint pain, and conjunctivitis, which can easily be confused with other mosquito-borne diseases. However, Zika virus infection, particularly in pregnant women, can lead to severe congenital abnormalities, including microcephaly in newborns, posing a significant public health threat.

Traditional diagnostic methods, such as reverse transcription polymerase chain reaction (RT-PCR), offer high specificity but require specialized laboratory equipment and expertise. Additionally, RT-PCR may yield false-negative results in later stages of infection when viral loads decline. Serological tests, which detect IgG and IgM antibodies, provide evidence of infection and are particularly useful for individuals in later stages of infection or those who have recovered. IgM antibodies typically appear within days of infection, indicating recent exposure, while IgG antibodies develop weeks or months later, suggesting prior infection or immunity. However, conventional serological tests are often time-consuming and impractical for rapid clinical responses.

BTNX's Rapid Response™ Zika Virus IgG/IgM Antibody Test Kit addresses this urgent diagnostic need. Utilizing qualitative immunochromatographic technology, the kit rapidly detects Zika virus IgG and IgM antibodies in human whole blood, serum, or plasma samples, providing supplementary diagnostic information.

The test kit operates on the principle of immunochromatography. When a sample is applied, any Zika virus IgG or IgM antibodies present bind to pre-coated Zika virus antigens in the kit, forming antigen-antibody complexes. These complexes migrate along the test strip and bind to anti-human IgG or IgM antibodies immobilized in the test line regions, producing visible red lines. A control line, which must appear for the test to be valid, confirms proper test functionality.

• Product Name: Rapid Response™ Zika Virus IgG/IgM Antibody Test Kit
• Product Code: ZIKMG-13C40
• Targets: Zika virus IgG and IgM antibodies
• Sample Types: Human whole blood, serum, or plasma
• Test Format: Qualitative
• Pack Size: 40 tests per kit
• Result Time: 10 minutes
• Storage Conditions: 2-30°C (35.6-86°F)
• Test Principle: Qualitative immunochromatographic assay

The kit is designed for simplicity, requiring only the addition of the sample to the test well followed by buffer. Results are available within 10 minutes, with no need for complex instrumentation. This makes the test suitable for various settings, including primary care facilities, field epidemiological investigations, and emergency screenings.

Results are determined by the presence of test and control lines. The control line (C) must appear for the test to be valid. The appearance of the IgG line (G) indicates Zika virus IgG antibodies, suggesting past infection or immunity, while the IgM line (M) indicates recent infection. The combination of lines provides preliminary information about the timing of infection:

• Only C line: Negative for Zika virus IgG and IgM antibodies.
• C and G lines: Positive for IgG antibodies, indicating past infection or immunity.
• C and M lines: Positive for IgM antibodies, suggesting recent infection.
• C, G, and M lines: Positive for both IgG and IgM antibodies, likely indicating recent infection with an ongoing immune response.

1. Early Screening and Diagnosis: Facilitates rapid identification of suspected cases during outbreaks, enabling timely isolation and containment.
2. Auxiliary Diagnosis: Complements nucleic acid testing to enhance diagnostic accuracy.
3. Epidemiological Surveys: Supports large-scale assessments of infection rates and immunity in populations.
4. Prenatal Monitoring: Aids in early detection of infections in pregnant women, allowing for appropriate maternal and fetal interventions.
5. Traveler Health Screening: Provides rapid health evaluations for travelers to or from Zika-endemic regions.

The development and application of the test kit are grounded in foundational research on Zika virus, including:

• Hayes EB (2009) Zika virus outside Africa. Emerg Infect Dis 15: 1347–1350.
• Simpson DI (1964) Zika virus infection in man. Trans R Soc Trop Med Hyg 58:335–338.
• Bearcroft WG (1956) Zika virus infection experimentally induced in a human volunteer. Trans R Soc Trop Med Hyg 50: 442–448.

The test kit is intended for use as described in the product instructions. Users should carefully follow all provided guidelines to ensure accurate results.